Engineering Better CAR T Cells: An Interview with CRI STAR Yvonne Chen, PhD

In this webinar for patients and caregivers, Dr. Yvonne Chen, a CRI Lloyd J. Old STAR, discusses how she has developed new strategies to improve CAR T cells -- a type of immunotherapy involving genetically engineered T cells capable of targeting specific cancer cells.
Dr. Chen is a co-director of UCLA’s Jonsson Comprehensive Cancer Center Tumor Immunology Program, and also is an associate professor at UCLA across several scientific disciplines. An inaugural CRI Lloyd J. Old STAR, Dr. Chen is determined to gain an understanding of the sequence-structure-function relationship in CARs to engineer more rational CAR designs. Additionally, she seeks to design revolutionary CARs that can attack multiple carcinogenic targets.
Funding for the CRI "Cancer Immunotherapy and You" webinar series is generously provided by Bristol Myers Squibb as well as Alkermes and Lilly Oncology.
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. www.cancerresearch.org
Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.

[@alohatvj]

I just heard about CAR-T cell therapy a few weeks ago. It sounds like a cancer fighting game changer. I hope many lives can be saved from this therapy.

[@Optunity]

Thank you for saving my lives and many children and young adults with gbm

[@alptekinakturk4185]

CAR-T therapy will change medicine forever. This will be remembered like the discovery of DNA in 2050s.

[@flightangel9746]

Are there any cancer patients with solid tumors receiving the CAR-T cell therapy?

[@tehdreamer]

Trials ungoing i believe, the deep state pharma will make sure they can suck every bit of penny before they allow to release it.

[@alicekigurumi6325]

In theory we cannot infuse more new Car T cell over time and chain infusion to replace tired T cells.😢 This could be like maintenance therapy for this treatment or booster dose.
Not that simple with it's behavior and has limitations.

[@joycemccloy]

I'm CD 20 Negative. I do have CD19 positive. What now?

[@Optunity]

Need more trials for gbm. #1 cancer killer in children and young adults